Developer docs
API playgroundTry for free, no card

Search company profiles

DEEPPATH LTD

Full company profile

uuid025o8ca

Namestring
DEEPPATH LTD
Legal namestring
DeepMed IO Ltd
Websiteurl
deeppath.io
Company typeenum
Private
Founded yearint
2017
Descriptiontext

DeepPath Ltd is a UK MedTech company founded in 2017 and headquartered at 3 Hardman Square, Spinningfields, Manchester. It develops DeepPath-LYDIA, a CE-Marked AI-powered decision support system (Class I in-vitro diagnostic under IVDD, certified May 2022) that assists histopathologists in detecting metastases on digitised whole slide images of H&E stained lymph node tissue. A single deep learning pipeline screens four cancer types—breast, colon, lung cancer and melanoma—covering approximately 43% of total cancer incidence, processing each slide in under 2.5 minutes at greater than 99% sensitivity and fewer than four false-positive tumour segments per lymph node.

The product is offered as either standalone software with basic case management or as an embedded component within third-party PACS systems, with cloud or on-premise deployment and support for Hamamatsu, 3D-Histech, Leica, Roche and Philips WSI formats. DeepPath monetises through annual unlimited-user subscription licences, a pay-as-you-go per-slide model, and a free trial for prospect validation, distributing via direct enterprise sales to hospital pathology departments and NHS trusts alongside its position as the first lymph-node metastasis detection solution featured on the Sectra Amplifier Marketplace.

Operationally, the company has secured its first named production deployment at UMC Utrecht (live October 2024, fully integrated into Sectra PACS) and is part of the PathLAKE NHS consortium targeting 17 million patients across Southern England. Capital structure is grant-led rather than VC-backed: a €4 million EIC Pathfinder grant (May 2022) via a consortium with MIDA Biotech, Leiden University and MIRCOD LLC, alongside earlier-stage support from SBRI Healthcare and the National Bank of Greece's nbgseeds program. No revenue, headcount, or venture equity rounds are disclosed; Konstantinos Vougas serves as Managing Director of the Greek operating entity DeepPath Monoprosopi IKE.

Short descriptiontext

DeepPath Ltd is a UK MedTech company that develops DeepPath-LYDIA, a CE-Marked AI system for detecting metastases in H&E stained digital pathology slides, sold to hospital pathology departments and academic medical centers across the UK, Netherlands, and additional European and US markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersManchester, United Kingdom
HQ citystring
Manchester
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology software, clinical decision support, metastasis detection AI, histopathology AI, cancer diagnostic software
Industry1 code
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code1 code
  • Software Publishers5132
SIC code2 codes
  • Services-Health Services8000
  • Services-Prepackaged Software7372
Product category
Digital Pathology Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Licensing (Yearly Subscription)
TypeSubscription Recurring
Description

Yearly licence with unlimited users based on system usage as estimated from past data. Provides ongoing access to DeepPath-LYDIA with support and updates.

deeppath.io
2Pay-as-You-Go Usage
TypeUsage Based
Description

Fixed cost per microscope slide analysed. Flexible consumption-based model that allows customers to pay only for actual usage.

deeppath.io
3Free Trial
TypeFreemium
Description

Customers can try LYDIA on their samples for free before committing to a paid licensing option.

deeppath.io
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Pricing details3 tiers
1Free Trial - Try before you buy
ModelFreemiumBilling cadencePay-as-you-go
Notes

Customers can try LYDIA on their own samples for free. If satisfied with results, paid licensing options are offered.

deeppath.io
2Yearly Licence - Unlimited users
ModelSubscriptionBilling cadenceAnnual
Notes

Yearly licence with unlimited users based on system usage as estimated from past data. Early-access discounts apply.

deeppath.io
3Pay as You Use - Per slide pricing
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Fixed cost per microscope slide analysed. Provides flexibility for variable-volume usage.

deeppath.io
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1DeepPath-LYDIA
Description

CE-Marked AI-powered decision support system for detecting metastases on digitised microscope slides of H&E stained Lymph Nodes, supporting breast, colon, lung cancer and melanoma detection.

deeppath.io
Core offering1 text field

DeepPath develops and sells DeepPath-LYDIA, a CE-Marked AI-powered clinical decision support system that detects metastatic regions on digitised Whole Slide Images of H&E stained lymph node tissue for breast, colon, lung cancer and melanoma. The product is offered as standalone software with basic case management or as an integrated component within third-party PACS systems (notably Sectra), with cloud or on-premise deployment options. Revenue is generated via annual enterprise licences (unlimited users) and pay-per-slide usage pricing, supplemented by a free trial.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 5x acceleration of diagnostic process
+4 more records
Product overview1 text field

DeepPath is a MedTech company offering a single unified AI product: DeepPath – LYDIA. This AI-powered decision support system is designed to assist histopathologists in cancer staging by detecting metastatic regions on digitised microscope slides. The system is CE-Marked as an in-vitro diagnostic product and can be deployed either on-cloud or on-premise. It is offered either as standalone software with basic case management or as an integrated component within third-party Picture Archiving and Communication Systems (PACS), particularly the Sectra Digital Pathology platform.

Product and service1 record
1DeepPath – LYDIA
CategoryDigital pathology / clinical decision support software
Description

AI-powered CE-Marked decision support system that analyses digitised Whole Slide Images of H&E stained lymph node tissue to detect metastatic regions across breast, colon, lung cancer and melanoma. Generates probabilistic heatmaps and tumour segments, processes slides in under 2.5 minutes with sensitivity above 99%, and is offered either as standalone software with basic case management or as an integrated component within PACS systems such as Sectra. Sold to hospital pathology departments, NHS Trusts, and academic medical centers via annual subscription or pay-per-slide pricing.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1UMC Utrecht
Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2024-10-09
Description

University Medical Center Utrecht deployed DeepPath-LYDIA in production, fully integrated into the Sectra PACS system. UMC Utrecht are pioneers in digital pathology and serve as a reference customer for the technology.

deeppath.io
2PathLAKE (NHS Trusts Consortium)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-10-09
Description

PathLAKE consortium of NHS Trusts in Southern England has DeepPath-LYDIA under procurement. This represents one of the world's largest clinical implementations of digital pathology and AI, targeting 17 million NHS patients.

deeppath.io
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-12-20
Description

DeepPath-LYDIA completed integration with Sectra Digital Pathology solution and is featured on the Sectra Amplifier Marketplace. DeepPath is a certified Sectra Amplifier Integrator. The integration allows histopathologists to access AI analysis without leaving the Sectra workflow.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-06
Description

MIDA Biotech B.V. (an Orgenesis Inc. company) is a consortium partner in the €4m Pathfinder grant for AI-powered autologous IPCS manufacturing platform to democratize personalized cell therapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-06
Description

Leiden University is a consortium partner in the €4m Pathfinder grant for AI-powered platform development to democratize autologous cell therapy manufacturing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-06
Description

MIRCOD LLC is a consortium partner in the €4m Pathfinder grant for AI-powered platform development to democratize autologous cell therapy manufacturing.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Major UK cancer treatment hospital collaborating with DeepPath on histopathology AI development and validation.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Leading UK university with medical school collaborating with DeepPath on histopathology AI research and development.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Major NHS Trust in Manchester collaborating with DeepPath on digital pathology AI implementation.

10NYU (New York University)
Strategic tierKeyTypeStrategic or Co-development Partner
Description

International academic partner collaborating with DeepPath on histopathology AI research and development.

deeppath.io
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Greek university collaborating with DeepPath on histopathology AI research.

12Manchester Cancer Research Center
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cancer research center collaborating with DeepPath on histopathology AI for cancer diagnostics.

deeppath.io
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ibex builds AI-based cancer diagnostics for pathology, including breast and prostate cancer detection deployed in routine clinical use across multiple health systems. Comparable as a CE-marked AI pathology decision-support vendor with multi-cancer ambitions and similar hospital pathology customer base.

TypeDirect peer
Description

PathAI applies deep learning to histopathology for cancer diagnosis and biomarker discovery, partnering with academic medical centers and biopharma. Comparable AI pathology peer with similar use cases in oncology diagnostics and a comparable research-and-commercial footprint.

TypeDirect peer
Description

Lunit provides AI solutions for cancer diagnostics including Lunit SCOPE, a CE-marked AI for pathology biomarker analysis. Comparable as an AI pathology vendor with multi-cancer products targeting hospital and reference lab customers globally.

TypeEmerging player
Description

Aiosyn is an emerging AI pathology company focused on computational pathology for kidney and prostate cancer diagnostics. Comparable emerging peer with similar deep-learning approach to cancer detection on whole slide images for hospital pathology customers.

TypeDirect peer
Description

Mindpeak develops AI-based image analysis for histopathology, including breast and prostate cancer detection, integrated with major PACS and slide scanner vendors. Comparable as a European AI pathology peer targeting pathology department workflows.

TypeDirect peer
Description

Paige develops AI-powered clinical decision support for digital pathology, with FDA-cleared products for prostate and breast cancer detection. Directly comparable as an AI pathology decision-support vendor serving hospital pathology departments with deep learning on whole slide images.

TypeDirect peer
Description

Qritive builds AI-powered clinical decision support tools for pathology across multiple cancer types including breast, lung, colon, and prostate. Directly comparable in offering AI decision support for multi-cancer metastasis detection in hospital pathology workflows.

TypeOthers
Description

Sectra is the digital pathology platform provider whose Amplifier Marketplace distributes DeepPath-LYDIA. While not a direct AI competitor, Sectra is the dominant distribution partner and infrastructure provider and is highly relevant as both channel partner and platform dependency.

TypeDirect peer
Description

Proscia offers a digital pathology platform with embedded AI applications for cancer detection, including Concentriq for diagnostic workflows. Comparable as a digital pathology platform vendor offering AI decision-support capabilities to hospital pathology departments.

TypeDirect peer
Description

Owkin develops AI for pathology and oncology, including MSIntuit, an AI diagnostic for microsatellite instability in colorectal cancer. Comparable as an AI-on-histopathology vendor targeting oncology decision support and integrated PACS workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DEEPPATH LTD

Digital Pathology Softwaredeeppath.io

DeepPath Ltd is a UK MedTech company that develops DeepPath-LYDIA, a CE-Marked AI system for detecting metastases in H&E stained digital pathology slides, sold to hospital pathology departments and academic medical centers across the UK, Netherlands, and additional European and US markets.

What DEEPPATH LTD does

DeepPath Ltd is a UK MedTech company founded in 2017 and headquartered at 3 Hardman Square, Spinningfields, Manchester. It develops DeepPath-LYDIA, a CE-Marked AI-powered decision support system (Class I in-vitro diagnostic under IVDD, certified May 2022) that assists histopathologists in detecting metastases on digitised whole slide images of H&E stained lymph node tissue. A single deep learning pipeline screens four cancer types—breast, colon, lung cancer and melanoma—covering approximately 43% of total cancer incidence, processing each slide in under 2.5 minutes at greater than 99% sensitivity and fewer than four false-positive tumour segments per lymph node.

The product is offered as either standalone software with basic case management or as an embedded component within third-party PACS systems, with cloud or on-premise deployment and support for Hamamatsu, 3D-Histech, Leica, Roche and Philips WSI formats. DeepPath monetises through annual unlimited-user subscription licences, a pay-as-you-go per-slide model, and a free trial for prospect validation, distributing via direct enterprise sales to hospital pathology departments and NHS trusts alongside its position as the first lymph-node metastasis detection solution featured on the Sectra Amplifier Marketplace.

Operationally, the company has secured its first named production deployment at UMC Utrecht (live October 2024, fully integrated into Sectra PACS) and is part of the PathLAKE NHS consortium targeting 17 million patients across Southern England. Capital structure is grant-led rather than VC-backed: a €4 million EIC Pathfinder grant (May 2022) via a consortium with MIDA Biotech, Leiden University and MIRCOD LLC, alongside earlier-stage support from SBRI Healthcare and the National Bank of Greece's nbgseeds program. No revenue, headcount, or venture equity rounds are disclosed; Konstantinos Vougas serves as Managing Director of the Greek operating entity DeepPath Monoprosopi IKE.

DEEPPATH LTD firmographics

Firmographics
Name
DEEPPATH LTD
Legal name
DeepMed IO Ltd
Website
https://deeppath.io
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
DeepPath Ltd is a UK MedTech company that develops DeepPath-LYDIA, a CE-Marked AI system for detecting metastases in H&E stained digital pathology slides, sold to hospital pathology departments and academic medical centers across the UK, Netherlands, and additional European and US markets.
Ownership category
akta.pro rank

DEEPPATH LTD industry classification

Industry
Product category
Digital Pathology Software
NAICS
Software Publishers (5132)
SIC
Services-Health Services (8000), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Digital pathology software
  • Clinical decision support
  • Metastasis detection AI
  • Histopathology AI
  • Cancer diagnostic software

Where DEEPPATH LTD is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

DEEPPATH LTD business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Software Licensing (Yearly Subscription): Yearly licence with unlimited users based on system usage as estimated from past data. Provides ongoing access to DeepPath-LYDIA with support and updates.
  2. Pay-as-You-Go Usage: Fixed cost per microscope slide analysed. Flexible consumption-based model that allows customers to pay only for actual usage.
  3. Free Trial: Customers can try LYDIA on their samples for free before committing to a paid licensing option.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree Trial - Try before you buy
SubscriptionAnnualYearly Licence - Unlimited users
Usage-basedPay-as-you-goPay as You Use - Per slide pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

DEEPPATH LTD product offering

Product offering

Core offering

DeepPath develops and sells DeepPath-LYDIA, a CE-Marked AI-powered clinical decision support system that detects metastatic regions on digitised Whole Slide Images of H&E stained lymph node tissue for breast, colon, lung cancer and melanoma. The product is offered as standalone software with basic case management or as an integrated component within third-party PACS systems (notably Sectra), with cloud or on-premise deployment options. Revenue is generated via annual enterprise licences (unlimited users) and pay-per-slide usage pricing, supplemented by a free trial.

Product overview

DeepPath is a MedTech company offering a single unified AI product: DeepPath – LYDIA. This AI-powered decision support system is designed to assist histopathologists in cancer staging by detecting metastatic regions on digitised microscope slides. The system is CE-Marked as an in-vitro diagnostic product and can be deployed either on-cloud or on-premise. It is offered either as standalone software with basic case management or as an integrated component within third-party Picture Archiving and Communication Systems (PACS), particularly the Sectra Digital Pathology platform.

Differentiator

Problem solved

Functional benefit

Brands

  • DeepPath-LYDIA: CE-Marked AI-powered decision support system for detecting metastases on digitised microscope slides of H&E stained Lymph Nodes, supporting breast, colon, lung cancer and melanoma detection.

Products and services

  • DeepPath – LYDIA AI-powered CE-Marked decision support system that analyses digitised Whole Slide Images of H&E stained lymph node tissue to detect metastatic regions across breast, colon, lung cancer and melanoma. Generates probabilistic heatmaps and tumour segments, processes slides in under 2.5 minutes with sensitivity above 99%, and is offered either as standalone software with basic case management or as an integrated component within PACS systems such as Sectra. Sold to hospital pathology departments, NHS Trusts, and academic medical centers via annual subscription or pay-per-slide pricing.

Quantifiable outcome

  • Up to 5x acceleration of diagnostic process
  • +4 more outcomes

Companies that use DEEPPATH LTD

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

DEEPPATH LTD technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature4 records

DEEPPATH LTD partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered key, flagship, core and minor.

  • UMC UtrechtkeyStrategic or Co-development Partner · 9 October 2024University Medical Center Utrecht deployed DeepPath-LYDIA in production, fully integrated into the Sectra PACS system. UMC Utrecht are pioneers in digital pathology and serve as a reference customer for the technology.
  • PathLAKE (NHS Trusts Consortium)flagshipStrategic or Co-development Partner · 9 October 2024PathLAKE consortium of NHS Trusts in Southern England has DeepPath-LYDIA under procurement. This represents one of the world's largest clinical implementations of digital pathology and AI, targeting 17 million NHS patients.
  • Sectra (Spectra Amplifier)coreTechnology or Integration · 20 December 2022DeepPath-LYDIA completed integration with Sectra Digital Pathology solution and is featured on the Sectra Amplifier Marketplace. DeepPath is a certified Sectra Amplifier Integrator. The integration allows histopathologists to access AI analysis without leaving the Sectra workflow.
  • MIDA Biotech B.V. (Orgenesis Inc.)coreStrategic or Co-development Partner · 6 May 2022MIDA Biotech B.V. (an Orgenesis Inc. company) is a consortium partner in the €4m Pathfinder grant for AI-powered autologous IPCS manufacturing platform to democratize personalized cell therapy.
  • Leiden UniversitycoreStrategic or Co-development Partner · 6 May 2022Leiden University is a consortium partner in the €4m Pathfinder grant for AI-powered platform development to democratize autologous cell therapy manufacturing.
  • MIRCOD LLCcoreStrategic or Co-development Partner · 6 May 2022MIRCOD LLC is a consortium partner in the €4m Pathfinder grant for AI-powered platform development to democratize autologous cell therapy manufacturing.
  • The Christie NHS Foundation TrustkeyStrategic or Co-development PartnerMajor UK cancer treatment hospital collaborating with DeepPath on histopathology AI development and validation.
  • UCL (University College London)keyStrategic or Co-development PartnerLeading UK university with medical school collaborating with DeepPath on histopathology AI research and development.
  • Manchester University NHS Foundation TrustkeyStrategic or Co-development PartnerMajor NHS Trust in Manchester collaborating with DeepPath on digital pathology AI implementation.
  • NYU (New York University)keyStrategic or Co-development PartnerInternational academic partner collaborating with DeepPath on histopathology AI research and development.
  • University of AthensminorStrategic or Co-development PartnerGreek university collaborating with DeepPath on histopathology AI research.
  • Manchester Cancer Research CenterminorStrategic or Co-development PartnerCancer research center collaborating with DeepPath on histopathology AI for cancer diagnostics.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

DEEPPATH LTD competitors and assessment

Company assessment

Direct peers

  • Ibex Medical Analytics: Ibex builds AI-based cancer diagnostics for pathology, including breast and prostate cancer detection deployed in routine clinical use across multiple health systems. Comparable as a CE-marked AI pathology decision-support vendor with multi-cancer ambitions and similar hospital pathology customer base.
  • PathAI: PathAI applies deep learning to histopathology for cancer diagnosis and biomarker discovery, partnering with academic medical centers and biopharma. Comparable AI pathology peer with similar use cases in oncology diagnostics and a comparable research-and-commercial footprint.
  • Lunit: Lunit provides AI solutions for cancer diagnostics including Lunit SCOPE, a CE-marked AI for pathology biomarker analysis. Comparable as an AI pathology vendor with multi-cancer products targeting hospital and reference lab customers globally.
  • Mindpeak: Mindpeak develops AI-based image analysis for histopathology, including breast and prostate cancer detection, integrated with major PACS and slide scanner vendors. Comparable as a European AI pathology peer targeting pathology department workflows.
  • Paige.AI: Paige develops AI-powered clinical decision support for digital pathology, with FDA-cleared products for prostate and breast cancer detection. Directly comparable as an AI pathology decision-support vendor serving hospital pathology departments with deep learning on whole slide images.
  • Qritive: Qritive builds AI-powered clinical decision support tools for pathology across multiple cancer types including breast, lung, colon, and prostate. Directly comparable in offering AI decision support for multi-cancer metastasis detection in hospital pathology workflows.
  • Proscia: Proscia offers a digital pathology platform with embedded AI applications for cancer detection, including Concentriq for diagnostic workflows. Comparable as a digital pathology platform vendor offering AI decision-support capabilities to hospital pathology departments.
  • Owkin: Owkin develops AI for pathology and oncology, including MSIntuit, an AI diagnostic for microsatellite instability in colorectal cancer. Comparable as an AI-on-histopathology vendor targeting oncology decision support and integrated PACS workflows.

Emerging players

  • Aiosyn: Aiosyn is an emerging AI pathology company focused on computational pathology for kidney and prostate cancer diagnostics. Comparable emerging peer with similar deep-learning approach to cancer detection on whole slide images for hospital pathology customers.

Others

  • Sectra: Sectra is the digital pathology platform provider whose Amplifier Marketplace distributes DeepPath-LYDIA. While not a direct AI competitor, Sectra is the dominant distribution partner and infrastructure provider and is highly relevant as both channel partner and platform dependency.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

DEEPPATH LTD social profiles

Digital presence

DEEPPATH LTD compliance and trust

Trust signal

Compliance1 record

DEEPPATH LTD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DEEPPATH LTD leadership team

Management profile

Number of profiles

Profiles1 record

DEEPPATH LTD funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DEEPPATH LTD M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DEEPPATH LTD

What does DEEPPATH LTD do?

DeepPath develops and sells DeepPath-LYDIA, a CE-Marked AI-powered clinical decision support system that detects metastatic regions on digitised Whole Slide Images of H&E stained lymph node tissue for breast, colon, lung cancer and melanoma. The product is offered as standalone software with basic case management or as an integrated component within third-party PACS systems (notably Sectra), with cloud or on-premise deployment options. Revenue is generated via annual enterprise licences (unlimited users) and pay-per-slide usage pricing, supplemented by a free trial.

Is DEEPPATH LTD a public or private company?

DEEPPATH LTD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DEEPPATH LTD founded?

DEEPPATH LTD was founded in 2017. It employs 1 to 10 people.

Where is DEEPPATH LTD based?

DEEPPATH LTD is headquartered in Manchester, United Kingdom, in the Europe region.

How does DEEPPATH LTD make money?

Three revenue lines are on record. Software Licensing (Yearly Subscription) is the primary driver. The others are pay-as-You-Go Usage and free Trial.

Who are DEEPPATH LTD's main competitors?

Direct peers on record are Ibex Medical Analytics, PathAI, Lunit, Mindpeak, Paige.AI, Qritive, Proscia and Owkin. Aiosyn is listed as an emerging player. Sectra is listed as an others.

Does DEEPPATH LTD have an API?

No public API is recorded for DEEPPATH LTD.

What industry is DEEPPATH LTD in?

DEEPPATH LTD's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 5132 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales